A phase ii study of carboplatin in nasopharyngeal carcinoma

Kwan H. Chi, Yuan C. Chang, Wing K. Chan, Jacqueline M. Liu, Chi K. Law, Su S. Lo, Chih H. Shu, Shan H. Yen, Jacqueline Whang-Peng, Kuang Y. Chen

研究成果: 雜誌貢獻文章同行評審

12 引文 斯高帕斯(Scopus)

摘要

This is a phase II study to evaluate the efficacy and toxicity of short-course carboplatin in advanced-stage nasopharyngeal carcinoma (NPC). Thirty-three previously untreated stage III-IV NPC patients were studied. Carboplatin was given as a rapid intravenous injection every 3 weeks. The dose of carboplatin was calculated according to the individual patient’s creatinine clearance and desired platelet nadir of 75,000/μl according to the Egorin formula. Response and toxicity were evaluated. Thirty-two patients were evaluated for response. The median age was 54 years, range 30-70 years. Twenty-four patients had local regional disease and 8 patients had metastatic disease. The median dose of carboplatin given was 415 mg/m2 (range 91-791 mg/m2). Fourteen (44%) patients had a partial response with a 95% confidence interval of 26-62%. Fifteen (47%) patients had stable disease and 3 (9%) progressive disease. The overall median survival rate was not reached at 43 months. Overall toxicity was tolerable. Grade III-IV myelosuppression occurred in 4 (12%) patients. There were no other major toxicity- or treatment-related deaths. We conclude that carboplatin has a significant anticancer effect in advanced NPC. Thus carboplatin combination chemotherapy for the treatment of NPC is worthy of future clinical investigations.
原文英語
頁(從 - 到)203-207
頁數5
期刊Oncology (Switzerland)
54
發行號3
DOIs
出版狀態已發佈 - 1月 1 1997
對外發佈

ASJC Scopus subject areas

  • 腫瘤科
  • 癌症研究

指紋

深入研究「A phase ii study of carboplatin in nasopharyngeal carcinoma」主題。共同形成了獨特的指紋。

引用此